Review
Classic diseases revisited
Management of non-Hodgkin's lymphomas
P J Mounter, A L Lennard
Department
of Haematology, Royal Victoria Infirmary, Queen Victoria Road,
Newcastle upon Tyne, NE1 4LP,
UK
Accepted 2 September
1998
The non-Hodgkin's lymphomas (NHL) are a heterogenous
group of disorders characterised by malignant proliferation of lymphoid cells. The cellular origin is relatively well established with subtypes
corresponding to the various stages of lymphocyte differentiation. The
term encompasses a hotchpotch of conditions with very different morphological appearance, behaviour and clinical outcome. NHL comprise
2.4% of all cancers, with incidence increasing with age. The commonest
presentation is with progressive lymphadenopathy, though extranodal
manifestations are present in a significant proportion. The clinical
behaviour ranges from a benign, indolent course to rapidly progressive
disease; prognosis varies from weeks to many years. Treatment is
correspondingly diverse, from `watchful waiting' to high-dose
chemotherapy with bone marrow stem cell transplantation. Cure is
possible in an increasing number of patients and much interest
currently lies in identifying patients with high-risk disease
necessitating the use of intensive treatment regimens.
Keywords: non-Hodgkin's lymphoma
© 1999 by The Fellowship of Postgraduate Medicine
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
